Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Guy Lerebours

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Medecine Sciences : M/S|July 17, 2007
[Sinus rhythm: mechanisms and function]Guy Lerebours
Annals of the New York Academy of Sciences|March 26, 2011
Innovation in coronary artery disease and heart failure: clinical benefits of pure heart rate reduction with ivabradineEmmanuel Canet, Guy Lerebours, Jean-Paul Vilaine
Circulation|February 20, 2003
Antianginal and antiischemic effects of ivabradine, an I(f) inhibitor, in stable angina: a randomized, double-blind, multicentered, placebo-controlled trialJeffrey S Borer, Kim Fox, Patrice Jaillon, et al.
Journal of the American College of Cardiology|March 16, 2005
Effect of perindopril on the onset and progression of left ventricular dysfunction in Duchenne muscular dystrophyDenis Duboc, Christophe Meune, Guy Lerebours, et al.
British Journal of Clinical Pharmacology|January 26, 2006
Comparative effects of ivabradine, a selective heart rate-lowering agent, and propranolol on systemic and cardiac haemodynamics at rest and during exerciseRobinson Joannides, Nicholas Moore, Michaela Iacob, et al.
Lancet (London, England)|August 31, 2010
Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled studyKarl Swedberg, Michel Komajda, Michael Böhm, et al.
Lancet (London, England)|August 31, 2010
Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trialMichael Böhm, Karl Swedberg, Michel Komajda, et al.
Circulation|February 26, 2004
Long-term heart rate reduction induced by the selective I(f) current inhibitor ivabradine improves left ventricular function and intrinsic myocardial structure in congestive heart failurePaul Mulder, Stephane Barbier, Abdeslam Chagraoui, et al.
Circulation. Heart Failure|June 26, 2020
Comparison of Outcome Adjudication by Investigators and by a Central End Point Committee in Heart Failure Trials: Experience of the SHIFT Heart Failure StudyBenoît Tyl, José Lopez Sendon, Jeffrey S Borer, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Medecine Sciences : M/S|July 17, 2007
[Sinus rhythm: mechanisms and function]Guy Lerebours
Annals of the New York Academy of Sciences|March 26, 2011
Innovation in coronary artery disease and heart failure: clinical benefits of pure heart rate reduction with ivabradineEmmanuel Canet, Guy Lerebours, Jean-Paul Vilaine
Circulation|February 20, 2003
Antianginal and antiischemic effects of ivabradine, an I(f) inhibitor, in stable angina: a randomized, double-blind, multicentered, placebo-controlled trialJeffrey S Borer, Kim Fox, Patrice Jaillon, et al.
Journal of the American College of Cardiology|March 16, 2005
Effect of perindopril on the onset and progression of left ventricular dysfunction in Duchenne muscular dystrophyDenis Duboc, Christophe Meune, Guy Lerebours, et al.
British Journal of Clinical Pharmacology|January 26, 2006
Comparative effects of ivabradine, a selective heart rate-lowering agent, and propranolol on systemic and cardiac haemodynamics at rest and during exerciseRobinson Joannides, Nicholas Moore, Michaela Iacob, et al.
Lancet (London, England)|August 31, 2010
Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled studyKarl Swedberg, Michel Komajda, Michael Böhm, et al.
Lancet (London, England)|August 31, 2010
Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trialMichael Böhm, Karl Swedberg, Michel Komajda, et al.
Circulation|February 26, 2004
Long-term heart rate reduction induced by the selective I(f) current inhibitor ivabradine improves left ventricular function and intrinsic myocardial structure in congestive heart failurePaul Mulder, Stephane Barbier, Abdeslam Chagraoui, et al.
Circulation. Heart Failure|June 26, 2020
Comparison of Outcome Adjudication by Investigators and by a Central End Point Committee in Heart Failure Trials: Experience of the SHIFT Heart Failure StudyBenoît Tyl, José Lopez Sendon, Jeffrey S Borer, et al.
Pageof 1